CRP and polycystic ovary syndrome: A Cochrane meta-analysis of seven randomized controlled trials of 25D administration to patients with polycystic ovary syndrome and normal kidney function found significant decreases in serum high-sensitivity (hs) C-reactive protein (CRP) and malondialdehyde (a marker of oxidative stress) with increased total antioxidant capacity, but no effect on nitric oxide or total glutathione levels [27].